Articles

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.

PCI to Purchase Full Stake in Ajinomoto Althea

Videos

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes potential availability challenges brought on by supply chain obstacles.

The Future of Specialty Medicine

Pharma Pulse 4/24/25: Understanding True Meaning of Risk in Clinical Trial Operations, European Pharma Companies Push for Higher Drug Prices Amid US Tariff Threats 

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.

LogiPharma Europe 2025: Three Ways to Turn Sustainability Pledges Into Progress

The program measures a company’s air cargo supply chain efforts when it comes to quality, safety, and compliance.

IATA CEIV Celebrates a Decade of Enhancing Air Cargo Efficiency 

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the company’s operations, particularly in terms of cost and supply chain management in the US market.

Analyzing Tariffs’ Effect on the Biopharmaceutical Supply Chain

Pharma Pulse 4/23/25: Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation, Trump Assessing Slashing US Drug Prices to International Levels

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares insights on how sustainability has evolved from a compliance requirement to a key business strategy, driving operational efficiencies, innovation, and long-term growth.

LogiPharma Europe 2025: Driving Business Success Through Sustainability

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

Reducing Polypharmacy in Older Adults

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

News